Zoetis Inc. $ZTS Shares Purchased by Swedbank AB

Swedbank AB boosted its position in Zoetis Inc. (NYSE:ZTS) by 60.4% in the 3rd quarter, Holdings Channel reports. The fund owned 2,436,888 shares of the company’s stock after purchasing an additional 917,598 shares during the period. Swedbank AB’s holdings in Zoetis were worth $356,565,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Nova Wealth Management Inc. purchased a new stake in shares of Zoetis in the first quarter valued at $25,000. 1248 Management LLC purchased a new position in Zoetis during the first quarter worth about $27,000. Saudi Central Bank acquired a new stake in Zoetis in the 1st quarter worth about $29,000. REAP Financial Group LLC grew its holdings in Zoetis by 201.5% in the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after buying an additional 131 shares during the period. Finally, NewSquare Capital LLC increased its stake in shares of Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the topic of several research analyst reports. Argus reissued a “buy” rating and issued a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Morgan Stanley set a $160.00 price target on shares of Zoetis in a report on Thursday, December 18th. JPMorgan Chase & Co. lowered their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Finally, BTIG Research reissued a “buy” rating and set a $160.00 price target on shares of Zoetis in a research report on Wednesday, December 3rd. Six analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and an average price target of $160.18.

Zoetis Stock Performance

Shares of ZTS stock opened at $123.39 on Wednesday. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. The company has a market cap of $54.38 billion, a PE ratio of 20.77, a P/E/G ratio of 2.69 and a beta of 0.97. The company’s fifty day simple moving average is $128.09 and its 200-day simple moving average is $143.66. Zoetis Inc. has a 52 week low of $115.25 and a 52 week high of $177.40.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.42 billion. During the same period in the prior year, the company earned $1.58 EPS. The firm’s revenue was up .5% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 3rd. Stockholders of record on Tuesday, January 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. The ex-dividend date is Tuesday, January 20th. Zoetis’s payout ratio is 33.67%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.